The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis

Abstract Introduction This meta-analysis aims to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with recurrent ovarian cancer, with particular emphasis on those with platinum-resistant disease. Method A comprehensive search of PubMed, EMBASE, and the Cochrane Librar...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Qiling Dai, Jiawen Tang, Ting Du, Qin Huang
Format: Artigo
Jezik:Inglês
Izdano: Springer 2025-11-01
Serija:Discover Oncology
Teme:
Mirvetuximab soravtansine
Ovarian cancer
Folate receptor alpha
Meta-analysis
Online pristup:https://doi.org/10.1007/s12672-025-03933-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items